Scott T Avecilla, Farid Boulad, Karina Yazdanbakhsh, Michel Sadelain, Patricia A Shi
BACKGROUND: Adequate CD34+ collection efficiency (CE) is critical to achieve target CD34+ cell doses in hematopoietic progenitor cell (HPC) collections. Autologous HPC collection in sickle cell disease (SCD) is associated with unstable collection interfaces and low CD34+ CEs. We hypothesized that variables specific to SCD, activation of blood cells and elevated viscosity, might contribute to these issues and made adjustments to the collection process and procedure to address our hypothesis.
STUDY DESIGN AND METHODS: In two patients with SCD undergoing autologous HPC collection on our clinical trial (NCT02193191), we therefore implemented adjustments to the process and procedure in the following areas: proximity of RBC exchange to HPC collection, the type of anticoagulation, and the packing factor setting.
RESULTS: There was no collection interface instability. Our CD34+ CE1s were high at 70% and 51%, and granulocyte CE, platelet CE, and product granulocyte % were remarkably low. Product hematocrits were not as high as previously reported to be required to obtain adequate CEs. Interestingly, one HPC product showed a hemoglobin S (HbS) of 91% at the same time that the peripheral blood (PB) showed a HbS of 22%.
DISCUSSION: Adjustments to the HPC collection process and procedure were associated with adequate CD34+ CEs and low granulocyte and platelet contamination in HPC products from SCD patients. Given the discrepancy in the percentage of sickle RBCs in the product versus the PB, we hypothesize that CD34+ cells and RBCs may aggregate. Our interventions and hypothesis should be further investigated in larger studies.
Blood Adv. 2021 May 11;5(9):2403-2411
[PMID:
33956057]
Transfusion. 2016 Nov;56(11):2824-2832
[PMID:
27589225]
Thromb Haemost. 2007 Aug;98(2):392-6
[PMID:
17721622]
J Clin Invest. 2014 Apr;124(4):1462-5
[PMID:
24642460]
Vox Sang. 2020 Nov;115(8):722-728
[PMID:
32965032]
Curr Opin Hematol. 2020 Nov;27(6):415-422
[PMID:
32889828]
J Clin Invest. 1983 Jul;72(1):22-31
[PMID:
6874947]
Nature. 2015 Sep 24;525(7570):528-32
[PMID:
26374999]
Transfusion. 2016 May;56(5):1008-12
[PMID:
26919388]
Br J Haematol. 2019 Jul;186(2):286-299
[PMID:
30972754]
Eur J Clin Invest. 1985 Aug;15(4):188-91
[PMID:
2931280]
Transfusion. 2019 Feb;59(2):659-670
[PMID:
30537213]
Transfusion. 2021 Feb;61(2):526-536
[PMID:
33368343]
Haematologica. 2018 May;103(5):778-786
[PMID:
29472357]
Transfus Apher Sci. 2010 Dec;43(3):273-279
[PMID:
20951649]
Br J Haematol. 2019 Mar;184(5):873-876
[PMID:
29767405]
Blood Adv. 2018 Oct 9;2(19):2505-2512
[PMID:
30282642]
Am J Hematol. 2020 Sep;95(9):E239-E242
[PMID:
32401372]
Bone Marrow Transplant. 2001 Aug;28(3):311-2
[PMID:
11536001]
Transfusion. 2016 Feb;56(2):528-32
[PMID:
26395285]
Blood. 2004 Nov 15;104(10):3378-85
[PMID:
15271798]
Thromb Res. 2014 Feb;133(2):190-5
[PMID:
24368019]
Haematologica. 2018 May;103(5):770-777
[PMID:
29419425]
Transfusion. 2017 May;57(5):1142-1151
[PMID:
28150319]
N Engl J Med. 1997 Nov 27;337(22):1584-90
[PMID:
9371854]
Biomedicines. 2020 Feb 25;8(3):
[PMID:
32106422]
Ann Clin Lab Sci. 2017 Sep;47(5):551-555
[PMID:
29066481]
Haematologica. 2020 Feb 13;105(10):e497
[PMID:
33054091]
Am J Hematol. 2004 May;76(1):19-25
[PMID:
15114592]
Blood Cells Mol Dis. 2009 Jul-Aug;43(1):63-7
[PMID:
19356955]
J Clin Apher. 2007;22(6):339-41
[PMID:
18095304]
Blood Rev. 2016 Mar;30(2):111-8
[PMID:
26341565]
Blood. 1982 Jun;59(6):1121-7
[PMID:
7082818]
Am J Blood Res. 2013 May 05;3(2):107-23
[PMID:
23675563]
Transfusion. 2021 May;61(5):1518-1524
[PMID:
33713454]
Transfus Clin Biol. 2008 Feb-Mar;15(1-2):19-22
[PMID:
18501656]
